Progeston

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Progeston

Property Description
Active Ingredient Medroxyprogesterone Acetate (MPA)
Forms Tablets (Oral), Injectable Suspension (Depot)
Pharmacological Class Progestogen, Endocrine Agent
General Purpose Hormonal support and regulation
Origin Synthetic derivative of Progesterone

Progeston: Definition and Classification as a Progestogen

Progeston is a pharmaceutical preparation containing the active substance Medroxyprogesterone Acetate (MPA), which is definitively classified as a synthetic progestin and a Steroid Hormone Receptor Agonist. This substance falls within the Progestogen pharmacological class. As a synthetic derivative with a robust steroidal structure, MPA offers distinct stability and potency in activating progesterone receptors throughout the body, providing a reliable hormonal influence.

Medroxyprogesterone Acetate (MPA): Origin and General Purpose

The compound Medroxyprogesterone Acetate is chemically modified to be a highly stable synthetic derivative, specifically developed for measured absorption and action, unlike the body's natural progesterone. As a potent progestational agent, its general purpose is to actively modulate the endocrine system where progesterone activity is required. This mechanism provides hormonal support in scenarios where the body needs stabilization due to certain hormonal imbalances, such as managing abnormal uterine bleeding associated with hormonal issues.

Available Forms: Tablets and Injectable Depot Suspension

A key distinguishing factor for products containing MPA is the simultaneous availability of two core dosage forms and routes of administration. Progeston can be prescribed as Tablets for oral use or as a sterile Injectable Suspension administered intramuscularly or subcutaneously. The injectable form is a significant differentiating feature, classified as a depot preparation. This specific formulation provides a long-acting therapeutic effect, ensuring continuous progestational action without the need for strict daily dosing.

Regulatory References

  1. Medroxyprogesterone - StatPearls - NCBI Bookshelf
  2. Medroxyprogesterone acetate - DHPC | European Medicines Agency

What side effects are possible with Progeston?

Possible Side Effects and Safety Information

The official safety profile for Progeston (Medroxyprogesterone Acetate, MPA) outlines adverse reactions according to regulatory classifications, detailing their frequency and the body systems affected. These safety characteristics are based strictly on authoritative government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by how often they are expected to occur. Very Common (ge 1/10) effects listed in regulatory documents include headache, nervousness, abdominal pain, weight gain, and injection site reactions (with the depot form). Common effects (ge 1/100 to < 1/10) include depression, insomnia, nausea, acne, and menstrual irregularities like spotting or amenorrhea. The safety profile documents less frequent effects across systems including Vascular Disorders and Hepato-biliary Disorders.

Serious Adverse Reactions and Safety Constraints

The label highlights specific, clinically significant risks. Serious adverse reactions documented in official labeling include thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, stroke). A significant decrease in Bone Mineral Density (BMD) is a specific risk associated with the long-term use of the injectable depot formulation. Use is restricted by contraindications, which prohibit its use in individuals with conditions such as known or suspected hormone-dependent malignancies, undiagnosed genital bleeding, and severe hepatic impairment.

Population and Duration Patterns

The prescribing information notes specific time-related patterns, such as the frequent observation of menstrual bleeding irregularities during the initial months of therapy. For the depot form, the risk and severity of BMD loss are formally documented as increasing with the duration of exposure. Adolescents using the depot formulation are noted as a population requiring specific safety consideration due to the potential impact on bone mass acquisition.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Medroxyprogesterone Acetate overdose focuses strictly on the potential clinical signs and the required emergency response actions. The documented clinical manifestations generally encompass gastrointestinal and central nervous system effects, including nausea, vomiting, abdominal pain, dizziness, fatigue, and drowsiness.

A specific manifestation noted in regulatory labeling is the potential for withdrawal bleeding in women following an overdose event. Oral doses up to 3 grams per day have been reported as well tolerated in regulatory documents.

Mandatory Emergency Actions

For severe or life-threatening presentations, regulatory guidance mandates seeking immediate medical attention. Emergency services must be contacted immediately if a person exhibits critical signs, such as a seizure, trouble breathing, collapse, or the inability to be awakened (loss of consciousness).

The official management approach is defined as symptomatic and supportive care combined with the discontinuation of the medicine. No specific pharmacological antidote is known or documented in the official prescribing information for the treatment of this overdose. All suspected overdose cases require adherence to the documented emergency response statements.

Therapeutic Uses of Progeston

What Progeston Treats: Main Uses and Benefits

Progeston (Medroxyprogesterone Acetate) is used to help manage conditions and symptoms associated with hormonal imbalances. The application of this medication is relevant in contexts involving heightened systemic burden and contributes to easing the overall symptom load.

The medication is applied in addressing conditions presenting with disruptive symptom manifestations, including secondary amenorrhea, abnormal uterine bleeding due to hormonal issues, the symptom clusters of endometriosis, and specific advanced cancers like endometrial or renal carcinoma. It is also commonly used to help with long-term pregnancy prevention.

Symptom Relief for Discomfort and Instability

Progeston is applied across domains where additional symptomatic support is needed. It helps address symptom clusters involving disruptive menstrual cycles and is relevant for easing bleeding that is excessively heavy or prolonged. In conditions involving inflammatory or irritative processes, such as endometriosis, it may assist with symptoms related to physical discomfort. Separately, in oncology, it supports the patient during difficult episodes by easing symptoms related to systemic imbalance, such as poor appetite and weight loss.


Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Progeston provides support that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms, such as menstrual irregularity and hormone-driven pain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Progeston (Medroxyprogesterone Acetate)

Official regulatory information defines who may and must not use Progeston based on health status and physiological state. The medicine is primarily approved for use in Adult Women for hormonal and contraceptive indications. Use in Postmenarchal Adolescents is permitted, but specific caution regarding Bone Mineral Density (BMD) loss is noted, and the product is Not Indicated before Menarche.


Contraindications (Must Not Use)

Progeston is Contraindicated in populations with specific pre-existing conditions:

  • Known or Suspected Pregnancy.
  • Active Thrombophlebitis or a past history of Thromboembolic Disorders (e.g., blood clots, cerebral vascular disease).
  • Known or Suspected Malignancy of the Breast or Estrogen- or Progesterone-Dependent Neoplasia.
  • Significant Liver Disease or Acute Liver Disease.
  • Undiagnosed Abnormal Genital/Vaginal Bleeding.

Conditional and Restricted Use

  • Long-Term Use: The medicine is Not Recommended as a long-term (over 2 years) contraceptive method unless other options are inadequate, due to the risk of BMD loss.
  • Lactation: For exclusively breastfeeding women, initiation is restricted until the sixth post-partum week.
  • Specific Comorbidities: Patients with Diabetes Mellitus or renal/cardiac dysfunction require careful monitoring during therapy, as stated in the label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Progeston (Medroxyprogesterone Acetate) is primarily defined by pharmacokinetic interactions involving metabolic enzymes. The interactions are largely structured around the medicine's metabolism, which is mainly mediated by the CYP3A4 enzyme.

Interaction Type Interacting Medicines and Substances
Exposure Decrease Strong CYP3A4 inducers (e.g., Rifampin, Phenytoin), and the substance Aminoglutethimide.
Exposure Increase Strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin).

Co-administration with strong CYP3A4 inducers is expected to significantly decrease MPA concentrations, potentially reducing the overall effectiveness of the medicine. Conversely, co-administration with strong CYP3A4 inhibitors is expected to increase MPA concentrations. The herbal product St. John's wort is classified as a strong CYP3A inducer and is expected to decrease concentrations, while the beverage Grapefruit juice is expected to increase concentrations due to its inhibitory action.

No combinations are formally labeled as contraindicated due to interaction risk, and no mandatory timing rules are documented. Regulatory caution notes that patients with pre-existing osteoporosis risk factors, such as chronic use of certain anticonvulsants or corticosteroids, require careful consideration due to the potential for compounded risk to bone mineral density. The official regulatory structure classifies these as clinically significant interactions based on metabolic clearance.

Mechanism of Action

Receptor Binding and Gene Transcription

Progeston is an endogenous steroid hormone that functions primarily by binding to the Progestogen Receptor ( PR), a nuclear receptor. Upon ligand binding, the activated PR dimerizes and translocates to the cell nucleus, where it interacts with specific DNA sequences known as Progesterone Response Elements ( PREs). This interaction modifies the recruitment of coactivator and corepressor complexes, regulating the transcription rate of target genes.


Endocrine and Cellular Modulation

The transcriptional changes induced by PR activation influence multiple physiological pathways. In the reproductive system, this signaling induces secretory transformation in the endometrial stroma and epithelium. Systemically, Progeston modulates the secretion patterns of pituitary gonadotropins by exerting negative feedback on the hypothalamus.


Influence on Bone Metabolism

In bone tissue, Progeston modulates osteoclastogenesis by binding to PR on osteoblasts, thereby influencing the expression ratio of RANKL to Osteoprotegerin ( OPG). Furthermore, its effect in downregulating the NF-kappa B signaling pathway results in the modulation of inflammatory cytokine expression, which subsequently influences matrix metalloproteinase expression within structural tissues.

Dosage and Administration Information

Progeston (Medroxyprogesterone Acetate, MPA) is administered either orally as tablets or via deep injection as a long-acting suspension. The specific dosing regimen and schedule depend entirely on the prescribed form.

Administration Routes and Schedules

Administration Type Dosing Schedule Principle Dose Ranges
Oral Tablets Daily, in a short-term cyclic regimen over 5 to 14 consecutive days per course. Typically 5 mg to 10 mg daily.
Injectable Suspension Fixed long interval, administered every 12 to 14 weeks. 150 mg (Intramuscular) or 104 mg (Subcutaneous).

For oral administration, the tablets may be taken with or without food. High-dose injectable regimens used in specific scenarios can range from 400 mg to 1000 mg per week initially, reducing to a monthly maintenance dose. If using the suspension, the vial or syringe must be vigorously shaken just prior to use to ensure the drug is uniformly distributed for correct dosing.

Timing and Procedural Conditions

Injectable administration requires adherence to strict timing. For long-acting contraception, the first injection is given only during the first 5 days of a normal menstrual period, or within specific postpartum windows. If the interval between fixed-dose injections is greater than 13 weeks, the possibility of pregnancy must be excluded before the next dose is administered. While the dose is not required to be adjusted based on body weight, use of the injectable form for longer than two years is typically limited unless other methods are considered inadequate.

Recent Clinical Evidence

Research evidence / Overview of studies for Progeston


Evidence for Long-Term Pregnancy Prevention

Progeston was studied for long-term pregnancy prevention by setting up large-scale studies, including randomized trials and observational settings. Studies monitored outcomes related to functional imbalance, specifically tracking the frequency of pregnancy occurrence over defined time intervals. Findings describe patterns observed in the studies, reporting specific measurements of the measured frequency of pregnancy occurrence across diverse populations. Data show patterns related to changes in menstrual characteristics, including the incidence of irregular bleeding or amenorrhea observed in some studies.

Evidence for Endocrine and Menstrual Conditions

This area outlines the clinical trials and systematic reviews that investigated the compound’s evaluation for conditions related to hormonal imbalance, specifically secondary amenorrhea and abnormal uterine bleeding. Studies monitored the compound’s evaluation in women experiencing conditions characterized by fluctuating or episodic manifestations. The primary outcome studied for secondary amenorrhea was the physiological event of withdrawal bleeding. For abnormal uterine bleeding (AUB) linked to hormonal patterns, research explored changes related to endometrial histology. Findings indicate short-term changes were measured during the study period for both observed changes in acute AUB and patterns observed in subsequent cycle regulation.

Evidence for Oncology and Advanced Symptoms

Research examined high-dose Progeston in patients with conditions marked by functional limitations, specifically advanced endometrial and renal carcinoma. Studies monitored outcomes linked to physiological strain, tracking objective measures like outcomes describing changes in tumor size and research endpoints tracking time until progression. Data show patterns related to differences in observed survival periods across various cancer types, which helps contextualize how the condition was observed in the studied populations.

Research Gaps and Remaining Uncertainty

While studies have examined the compound across defined time intervals, long-term effects are not fully established, particularly regarding skeletal density with extended use. Certainty remains low for some long-term consequences, as many studies focus on short-term or episodic symptom patterns. Comparative evidence is lacking against many newer treatment options, meaning research is ongoing to fully contextualize Progeston within the current landscape. Data for certain groups, such as older adults, remain insufficient, and subgroup findings are uncertain for people with specific comorbid conditions.

Key Studies & References

  1. Medroxyprogesterone Injection: MedlinePlus Drug Information
  2. DEPO-PROVERA medroxyprogesterone acetate injectable suspension, USP (DailyMed Label for Oncology)
  3. Medroxyprogesterone - SEER*Rx Interactive Antineoplastic Drugs Database - National Cancer Institute (NCI) (Oncology Indication)
  4. [Updated] Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma - NPRA (Long-Term Safety/Research Gaps)

Frequently Asked Questions (FAQ)

Common questions about Progeston (FAQ)

Q: How quickly does Progeston usually start to have an effect?

According to official product information, the oral tablets are rapidly absorbed, reaching the highest concentration in the bloodstream within a few hours. In contrast, the long-acting injectable form is specifically designed as a depot preparation. This means it releases the medicine slowly and continuously over a period of several months to achieve its effects.


Q: Is Progeston used for both men and women?

For its hormonal and contraceptive uses, the medicine is primarily indicated for adult women. However, official regulatory information confirms that high-dose regimens have historically been studied and used in the management of certain advanced cancers, which are conditions that can affect both sexes.


Q: Does Progeston stay in your system for a long time after stopping it?

The period the medicine remains in your system depends on the form used. The oral tablets have a relatively short half-life, meaning they are processed out of the body in one to two days. However, the injectable form creates a long-lasting reservoir, and studies indicate that the return to normal fertility patterns can be delayed for a long period after the final injection.


Q: What if I forget to take a dose of Progeston, what do official documents say?

Official regulatory patient information for the oral tablets describes the procedure for missed doses. If a dose is missed, patient information describes procedures such as taking it as soon as remembered. However, if it is almost time for the next scheduled dose, the guidance states that the missed dose should be skipped and the regular schedule resumed, without taking two doses at once.


Q: Is Progeston considered safe for older adults?

Official regulatory text does not document geriatric-specific issues that are universally distinct from other populations. However, the official label notes that pre-existing conditions common in this age group, such as stroke, deep vein thrombosis, or cardiac dysfunction, may be linked to the need for careful monitoring during therapy. The research evidence section often notes that data for this population group is often insufficient.


Q: Do food or dairy products impact how Progeston works?

According to official labeling, the oral tablets can be taken with or without food, allowing for flexibility in administration. Specific advice regarding dairy products is not routinely detailed in the official product information, but the general rule about food applies.


Q: Does Progeston interact with herbal tea or caffeine?

Official drug interaction profiles highlight specific substances that affect the medicine's metabolism. For example, the herbal product St. John's wort is listed as a strong inducer of the CYP3A enzyme, which may lead to decreased levels of Progeston. General herbal teas or caffeine are not typically addressed in the official interaction warnings.


Q: What are the main research themes being investigated for Progeston currently?

Research and post-marketing surveillance continue to focus on resolving known areas of uncertainty. Key themes include further investigation into the potential for long-term effects on skeletal density associated with extended use. Studies are also ongoing to better contextualize the medicine’s performance compared to newer treatment options in various conditions.


Q: Is Progeston a type of hormone replacement therapy?

Progeston (Medroxyprogesterone Acetate) is classified as a progestogen, which provides hormonal support. According to official labeling, when it is prescribed alongside an estrogen, it forms part of Hormone Replacement Therapy (HRT). This combination is typically used to manage symptoms related to menopause, such as preventing the overgrowth of the uterine lining.


Q: Are there any known interactions between Progeston and alcohol?

Official regulatory information does not typically list a direct pharmacokinetic interaction between the medicine and alcohol. However, regulatory warnings note that chronic, excessive alcohol use is itself a risk factor for osteoporosis. This is relevant because the long-term use of the injectable form is associated with a specific risk of Bone Mineral Density (BMD) loss.


Q: How is Progeston eliminated from the body?

The medicine is processed and broken down by the body primarily in the liver. This metabolic process is carried out mostly by an enzyme known as CYP3A4. This enzyme is significant because the medicine's interactions with other drugs are largely determined by whether they also affect this metabolic pathway.


Q: Can I use Progeston if I am currently taking birth control pills?

Progeston itself is a progestin, and regulatory labels carry warnings about the combined use of progestins and estrogens. The official label describes potential risks associated with the use of progestin-containing products in combination with estrogen, including an increased risk of serious side effects like thromboembolic events.


Q: Is it possible to be allergic to Progeston?

Yes, regulatory information states that hypersensitivity (an allergic reaction) to Medroxyprogesterone Acetate or any component of the formulation is a contraindication for its use. Furthermore, the possibility of serious, sudden allergic reactions, known as anaphylaxis, has been documented in the official safety profile.


Q: Do specific genetic factors influence how Progeston works?

Official drug annotations show that the medicine's metabolism is mainly handled by the CYP3A4 enzyme system, which can exhibit differences in activity among individuals due to genetic variations. In the context of cancer use, the presence of specific markers, such as Estrogen Receptor status, is noted in regulatory information as a factor influencing expected outcome.


Q: Is Progeston a controlled substance?

Progeston is not regulated as a controlled substance under federal law by the U.S. Drug Enforcement Administration. This classification is usually applied to drugs with a recognized risk of dependence or misuse.


Q: Does Progeston have a Boxed Warning in the official regulatory label?

Yes, the official regulatory label for the injectable formulation includes a Boxed Warning. This is a prominent warning that highlights the risk of Loss of Bone Mineral Density (BMD) associated with its use. The oral tablets, when prescribed with an estrogen, also carry Boxed Warnings related to cardiovascular and cancer risks.


Q: Are there any specific laboratory tests required before starting Progeston?

The official guidance emphasizes that the possibility of pregnancy must be excluded before administering the injectable form after a certain time interval has passed. Regulatory information also notes that pre-existing conditions such as diabetes or heart/kidney issues are linked to the need for monitoring during therapy.


Q: Is Progeston used in managing symptoms related to menopause?

Yes, the medicine is officially indicated for use in combination with an estrogen to help manage certain symptoms of menopause. Specifically, it is prescribed to prevent the overgrowth of the uterine lining, known as endometrial hyperplasia, which can be a result of unopposed estrogen therapy.


Q: Can Progeston affect blood pressure readings?

Official regulatory warnings note that the medicine may cause fluid retention in some patients. Because of this potential for fluid accumulation, the regulatory text notes that pre-existing conditions such as hypertension (high blood pressure) or cardiac dysfunction are linked to the need for careful consideration.

How should Progeston be stored and disposed of?

How to Store and Dispose of Progeston (Medroxyprogesterone Acetate)

Official storage and disposal requirements for Progeston are mandatory to maintain product stability and ensure environmental safety.

Storage Requirements

Progeston oral tablets must be stored at Controlled Room Temperature, generally between 20°C and 25°C. They must be protected from excessive moisture and kept in the original, tightly closed container.

The injectable suspension must not be stored above 30°C and must not be frozen. Vials should be kept in the original carton to protect the contents from light. Before use, the suspension must be vigorously shaken.

All forms of Progeston must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local pharmaceutical waste requirements. The medication must not be thrown into household trash or flushed down drains, as the active substance should not be released into the environment. Used injectable components must be discarded using a puncture-proof sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Progeston found in:

A-Z Index: